Skip to main content

Table 1 Distribution of SARS-CoV-2-specific antibodies detection in COVID-19 patients

From: Detection of SARS-CoV-2-specific antibodies via rapid diagnostic immunoassays in COVID-19 patients

Week   Positives (%)
  Asymptomatic Symptomatic
Total RDT CMIA ELISA RTD CMIA ELISA
  IgM IgG IgM/IgG IgG IgG IgA IgM IgG IgM/IgG IgG IgG IgA
1 16 4/8 (50.0) 6/8 (75.0) 6/8 (75.0) 6/8 (75.0) 6/8 (75.0) 6/8 (75.0) 2/8 (25.0) 1/8 (12.5) 2/8 (25.0) 1/8 (12.5) 0/8 (0.0) 0/8 (0.0)
2 17 5/10 (50.0) 6/10 (60.0) 6/10 (60.0) 8/10 (80.0) 3/10 (30.0) 9/10 (90.0) 4/7 (57.1) 3/7 (42.9) 5/7 (71.4) 4/7 (57.1) 2/7 (28.6) 4/7 (57.1)
3 12 3/4 (75.0) 4/4 (100.0) 4/4 (100.0) 4/4 (100.0) 4/4 (100.0) 4/4 (100.0) 8/8 (100.0) 8/8 (100.0) 8/8 (100.0) 8/8 (100.0) 6/8 (75.0) 8/8 (100.0)
4 3 0.0 0.0 0.0 0.0 0.0 0.0 3/3 (100.0) 3/3 (100.0) 3/3 (100.0) 3/3 (100.0) 3/3 (100.0) 3/3 (100.0)
5 13 0.0 0.0 0.0 0.0 0.0 0.0 11/13 (84.6) 11/13 (84.6) 11/13 (84.6) 12/13 (92.3) 10/13 (76.9) 11/13 (84.6)
6 33 0.0 0.0 0.0 0.0 0.0 0.0 22/33 (66.7) 28/33 (84.8) 28/33 (84.8) 27/33 (81.8) 25/33 (75.8) 25/33 (75.8)
7 46 0.0 0.0 0.0 0.0 0.0 0.0 35/46 (76.1) 41/46 (89.1) 41/46 (89.1) 40/46 (87.0) 41/46 (89.1) 40/46 (87.0)
8 105 0.0 0.0 0.0 0.0 0.0 0.0 70/105 (66.7) 87/105 (82.9) 90/105 (85.7) 85/105 (81.0) 89/105 (84.8) 86/105 (81.9)
Total 245 12/22 (54.5) 16/22 (72.7) 16/22 (72.7) 18/22 (81.8) 13/22 (59.1) 19/22 (86.4) 155/223 (69.5) 182/223 (81.6) 188/223 (84.3) 180/223 (80.7) 176/223 (78.9) 177/223 (79.4)
  1. “Asymptomatic” refers to patients who had no symptoms but positive for SARS-CoV-2 by real-time reverse transcriptase PCR test. “Symptomatic” refers to patients who had one or more symptoms related to COVID-19 such as fever, cough, sore throat, or difficulty breathing
  2. RDT Rapid diagnosis test (nucleocapsid protein), CMIA Chemiluminescent microparticle immunoassay (nucleocapsid protein), ELISA Enzyme-linked immunosorbent assay (spike protein)